| Literature DB >> 35370483 |
Bernhard Langer1, Christian Kunow1.
Abstract
Background: In Germany-as worldwide-headache is one of the most frequent causes of self-medication. The dispensing of over-the-counter (OTC) medications may only be carried out by community pharmacies (CPs). In doing so, CPs have to ensure "adequate" counseling, for both self-purchase and purchase for a third party, which also occurs in everyday pharmacy practice. The aim of this study was to evaluate the quality of counseling for headache OTC medications in German CPs and, as the first study worldwide, to analyze whether and to what extent there are differences in counseling between self-purchase and purchase for a third party.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35370483 PMCID: PMC8967581 DOI: 10.1155/2022/5851117
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Self-purchase scenario [27].
| The SP entered the CP and said at the beginning of the conversation, “Hi, I need something for me for headache.” | |
| Questions asked by the pharmacy staff | Information given by the SP |
Purchase for a third-party scenario [27].
| The SP entered the CP and said at the beginning of the conversation, “Hi, my boyfriend/girlfriend needs something for headache.” | |
| Questions asked by the pharmacy staff | Information given by the SP |
Assessment form.
| Items | ||
|---|---|---|
| Yes | No | |
| Possible questions asked by pharmacy staff: | ||
| (1) What symptoms occur? | 1 | 0 |
| (2) How long have the symptoms been present? | 1 | 0 |
| (3) How often do the symptoms occur? | 1 | 0 |
| (4) Have other symptoms occurred? | 1 | 0 |
| (5) Are there other medical conditions? | 1 | 0 |
| (6) Which medications are taken regularly? | 1 | 0 |
| Possible information given by pharmacy staff: | ||
| (7) Information about dosage | 1 | 0 |
| (8) Information about duration | 1 | 0 |
| (9) Information about side effects | 1 | 0 |
Control variables as well as time and type of data collection.
| Control variables [literature source | Time of data collection | Type of data collection |
|---|---|---|
| CP quality certificate [ | After the visit | Exact measurement using a telephone query after completing all the visits |
| Gender of the SP [ | Before the visit | Exact measurement based on the gender of the SP |
| Age of the SP [ | Before the visit | Exact measurement based on the age of the SP |
| Gender of the pharmacy staff [ | During the visit | Exact measurement using visual impression of the SP |
| Age of the pharmacy staff [ | During the visit | Estimate using visual impression of the SP |
| Professional group of the pharmacy staff [ | After the visit | Exact measurement based on the name tag and the receipt and, if necessary, using a telephone query by the SP after completing the visit |
| Time of the visit [ | During the visit | Exact measurement using the SP's watch |
| Queue—customers waiting behind the SP [ | During the visit | Exact measurement using visual impression of the SP |
| Active ingredient [ | After the visit | Exact measurement using information of the package inserts |
Note: ∗The control variables were taken from the specific literature sources.
CPs, SPs, pharmacy staff, visits, and active ingredients characteristics by scenario type.
| Total | Self-purchase scenario | Purchase for a third-party scenario | McNemar test | |
|---|---|---|---|---|
|
|
|
| ||
| CP quality certificate | ||||
| (i) No | 76 (100) | 38 (50.0) | 38 (50.0) | n/a# |
| (ii) Yes | 76 (100) | 38 (50.0) | 38 (50.0) | |
| (iii) Not able to be determined | 16 (100) | 8 (50.0) | 8 (50.0) | |
|
| ||||
| Gender of the SP | ||||
| (i) Male | 84 (100) | 24 (28.6) | 60 (71.4) | <0.001 |
| (ii) Female | 84 (100) | 60 (71.4) | 24 (28.6) | |
|
| ||||
| Age of the SP | ||||
| (i) <30 | 102 (100) | 72 (70.6) | 30 (29.4) | <0.001 |
| (ii) 30–49 | 66 (100) | 12 (18.2) | 54 (81.8) | |
| (iii) ≥50 | 0 (0) | 0 (0) | 0 (0) | |
|
| ||||
| Gender of the pharmacy staff | ||||
| (i) Male | 30 (100) | 11 (36.7) | 19 (63.3) | 0.077 (0.250) |
| (ii) Female | 138 (100) | 73 (52.9) | 65 (47.1) | |
|
| ||||
| Age of the pharmacy staff | ||||
| (i) <30 | 16 (100) | 9 (56.3) | 7 (43.7) | 0.947# |
| (ii) 30–49 | 91 (100) | 45 (49.5) | 46 (50.5) | |
| (iii) 50 | 61 (100) | 30 (49.2) | 31 (50.8) | |
|
| ||||
| Professional group of the pharmacy staff | ||||
| (i) Pharmacist | 89 (100) | 44 (49.4) | 45 (50.6) | 0.773# |
| (ii) Nonpharmacist | 72 (100) | 37 (51.4) | 35 (48.6) | |
| (iii) Not able to be determined | 7 (100) | 3 (42.9) | 4 (57.1) | |
|
| ||||
| Time of the visit | ||||
| (i) 8:00 a.m.–12:00 p.m. | 26 (100) | 13 (50.0) | 13 (50.0) | 0.003# |
| (ii) 12:01 p.m.–4:00 p.m. | 85 (100) | 54 (63.5) | 31 (36.5) | |
| (iii) 4:01 p.m.–8:00 p.m. | 57 (100) | 17 (29.8) | 40 (70.2) | |
|
| ||||
| Queue—customers waiting behind the SP | ||||
| (i) No | 120 (100) | 67 (55.8) | 53 (44.2) | 0.029 |
| (ii) Yes | 48 (100) | 17 (35.4) | 31 (64.6) | |
|
| ||||
| Active ingredient | ||||
| (iii) Paracetamol | 34 (100) | 23 (67.6) | 11 (32.4) | 0.153# |
| (iv) Ibuprofen | 101 (100) | 46 (45.5) | 55 (54.5) | |
| (v) Others | 33 (100) | 15 (45.5) | 18 (54.5) | |
# McNemar–Bowker test; n/a (not applicable); ∗significant at p < 0.05.
Assessment items and counseling score by scenario type.
| Total | Self-purchase scenario | Purchase for a third-party scenario | McNemar test | ||
|---|---|---|---|---|---|
|
|
|
| |||
| (1) What symptoms occur? | |||||
| (i) No | 107 (100) | 51 (47.7) | 56 (52.3) | 0.487 (0.076) | |
| (ii) Yes | 61 (100) | 33 (54.1) | 28 (45.9) | ||
|
| |||||
| (2) How long have the symptoms been present? | |||||
| (i) No | 151 (100) | 74 (49.0) | 77 (51.0) | 0.607 (0.100) | |
| (ii) Yes | 17 (100) | 10 (58.8) | 7 (41.2) | ||
|
| |||||
| (3) How often do the symptoms occur? | |||||
| (i) No | 139 (100) | 67 (48.2) | 72 (51.8) | 0.424 (0.077) | |
| (ii) Yes | 29 (100) | 17 (58.6) | 12 (41.4) | ||
|
| |||||
| (4) Have other symptoms occurred? | |||||
| (i) No | 124 (100) | 66 (53.2) | 58 (46.8) | 0.200 (0.133) | |
| (ii) Yes | 44 (100) | 18 (40.9) | 26 (59.1) | ||
|
| |||||
| (5) Are there other medical conditions? | |||||
| (i) No | 79 (100) | 46 (58.2) | 33 (41.8) | 0.066 (0.151) | |
| (ii) Yes | 89 (100) | 38 (42.7) | 51 (57.3) | ||
|
| |||||
| (6) Which medications are taken regularly? | |||||
| (i) No | 100 (100) | 49 (49.0) | 51 (51.0) | 0.868 (0.028) | |
| (ii) Yes | 68 (100) | 35 (51.5) | 33 (48.5) | ||
|
| |||||
| (7) Information about dosage given | |||||
| (i) No | 44 (100) | 23 (52.3) | 21 (47.3) | 0.864 (0.029) | |
| (ii) Yes | 124 (100) | 61 (49.2) | 63 (50.8) | ||
|
| |||||
| (8) Information about duration given | |||||
| (i) No | 105 (100) | 43 (41.0) | 62 (59.0) | 0.003 | |
| (ii) Yes | 63 (100) | 41 (65.1) | 22 (34.9) | ||
|
| |||||
| (9) Information about side effects given | |||||
| (i) No | 159 (100) | 78 (49.1) | 81 (50.9) | 0.453 (0.214) | |
| (ii) Yes | 9 (100) | 6 (66.7) | 3 (33.3) | ||
|
| |||||
| Counseling score | Mean (SD) | 3.0 (1.8) | 3.1 (1.9) | 2.9 (1.7) | 0.495# (0.053) |
| Median (IQR) | 3.0 (2.0) | 3.0 (2.0) | 3.0 (2.0) | ||
# Wilcoxon signed-rank test (Pearson's r); significant at p < 0.05.
Association between counseling level and scenario type.
| Variables | Total | Counseling level below average | Counseling level above average | COR (95% CI) |
| AOR (95% CI) |
|
|---|---|---|---|---|---|---|---|
|
|
|
| |||||
| Scenario type | |||||||
| (i) Self-purchase | 84 (100) | 66 (78.6) | 18 (21.4) | 1 | 0.701 | 1 | 0.278 |
| (ii) Purchase for a third party | 84 (100) | 68 (81.0) | 16 (19.0) | 0.863 (0.406–1.833) | 1.635 (0.673–3.972) | ||
|
| |||||||
| Control variables | |||||||
| CP quality certificate | |||||||
| (i) No | 76 (100) | 55 (72.4) | 21 (27.6) | 1 | 1 | ||
| (ii) Yes | 76 (100) | 65 (85.5) | 11 (14.5) | 0.443 (0.197–0.999) | 0.049 | 0.435 (0.188–1.006) | 0.052 |
| (iii) Not able to be determined | 16 (100) | 14 (87.5) | 2 (12.5) | 0.374 (0.078–1.789) | 0.218 | 0.329 (0.067–1.615) | 0.171 |
|
| |||||||
| Gender of the SP | |||||||
| (i) Male | 84 (100) | 73 (86.9) | 11 (13.1) | 1 | 1 | 0.779 | |
| (ii) Female | 84 (100) | 61 (72.6) | 23 (27.4) | 2.502 (1.130–5.540) | 0.024 | 1.194 (0.346–4.126) | |
|
| |||||||
| Age of the SP | |||||||
| (i) <30 | 102 (100) | 75 (73.5) | 27 (26.5) | 1 | 1 | 0.090 | |
| (ii) 30–49 | 66 (100) | 59 (89.4) | 7 (10.6) | 0.330 (0.134–0.809) | 0.015 | 0.283 (0.066–1.217) | |
| (iii) ≥50 | 0 (0) | 0 (0) | 0 (0) | — | — | — | — |
|
| |||||||
| Gender of the pharmacy staff | |||||||
| (i) Male | 30 (100) | 27 (90.0) | 3 (10.0) | 1 | 0.135 | ||
| (ii) Female | 138 (100) | 107 (72.5) | 31 (22.5) | 2.607 (0.741–9.174) | |||
|
| |||||||
| Age of the pharmacy staff | |||||||
| (i) <30 | 16 (100) | 11 (68.7) | 5 (31.3) | 1 | |||
| (ii) 30–49 | 91 (100) | 70 (76.9) | 21 (23.1) | 0.660 (0.206–2.114) | 0.484 | ||
| (iii) ≥50 | 61 (100) | 53 (86.9) | 8 (13.1) | 0.332 (0.091–1.209) | 0.085 | ||
|
| |||||||
| Professional group of the pharmacy staff | |||||||
| (i) Pharmacist | 89 (100) | 71 (79.8) | 18 (20.2) | 1 | |||
| (ii) Nonpharmacist | 72 (100) | 56 (77.8) | 16 (22.2) | 1.127 (0.528–2.408) | 0.758 | ||
| (iii) Not able to be determined | 7 (100) | 7 (100) | 0 (0) | 0 (0) | 0.999 | ||
|
| |||||||
| Time of the visit | |||||||
| (i) 8:00 a.m.–12:00 p.m. | 26 (100) | 21 (80.8) | 5 (19.2) | 1 | |||
| (ii) 12:01 p.m.–4:00 p.m. | 85 (100) | 66 (77.6) | 19 (22.4) | 1.209 (0.402–3.635) | 0.735 | ||
| (iii) 4:01 p.m.–8:00 p.m. | 57 (100) | 47 (82.5) | 10 (17.5) | 0.894 (0.272–2.939) | 0.853 | ||
|
| |||||||
| Queue—customers waiting behind the SP | |||||||
| (i) No | 120 (100) | 92 (76.7) | 28 (23.3) | 1 | |||
| (ii) Yes | 48 (100) | 42 (87.5) | 6 (12.5) | 0.469 (0.181–1.219) | 0.120 | ||
|
| |||||||
| Active ingredient | |||||||
| (i) Paracetamol | 34 (100) | 27 (79.4) | 7 (20.6) | 1 | |||
| (ii) Ibuprofen | 101 (100) | 76 (75.2) | 25 (24.8) | 1.269 (0.493–3.268) | 0.622 | ||
| (iii) Others | 33 (100) | 31 (93.9) | 2 (6.1) | 0.249 (0.048–1.301) | 0.099 | ||
COR: crude odds ratio; AOR adjusted odds ratio. significant at p < 0.05.